Sustained-release naltrexone: Novel treatment for opioid dependence

Expert Opinion on Investigational Drugs

Volumn 16, Issue 8, 2007, Pages 1285-1294

  Comer, Sandra D ^a,b   Sullivan, Maria A ^a,b   Hulse, Gary K ^b  

^a Department of Psychiatry ^*  (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Depot; Heroin; Implant; Naltrexone; Opioid; Sustained release

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DEPOTREX; DIAMORPHINE; GLYCOLIC ACID; LACTIC ACID; METHADONE; MICROSPHERE; MORPHINE; NALTREXONE; OPIATE; PLACEBO; UNCLASSIFIED DRUG; VIVITROL;

ALCOHOLISM; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG IMPLANTATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; FATIGUE; HEADACHE; HEROIN DEPENDENCE; HUMAN; INJECTION SITE REACTION; MULTIPLE DRUG ABUSE; NAUSEA; NEUROENDOCRINE DISEASE; NONHUMAN; OPIATE ADDICTION; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SKIN INDURATION; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE PREPARATION; WITHDRAWAL SYNDROME;

ANIMALS; DELAYED-ACTION PREPARATIONS; HUMANS; NALTREXONE; OPIOID-RELATED DISORDERS;

EID: 34548211018     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.8.1285     Document Type: Article

References (100)

1. OFFICE OF APPLIED STUDIES: Substance Abuse and Mental Health Services Administration (SAMHSA). The DASIS report: heroin - changes in how it is used: 1992 - 2002. Rockville, USA (17 December 2004).
2. MARK TL, WOODY GE, JUDAY T, KLEBER HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend. (2001) 61(2):195-206.
3. ZACNY JP, BIGELOW GE, COMPTON P et al.: College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcobol Depend. (2003) 69:215-232.
4. OFFICE OF APPLIED STUDIES: SAMHSA: Results from the 2003 National Survey on Drug use and Health: National Findings. NSDUH Series H-25, DHHS Publication No. SMA 04-3964. Rockville, MD (2004a).
5. SAMHSA: Office of Applied Studies. Results from the 2004 National Survey on Drug use and Health: National Findings. NSDUH Series H-28, DHHS Publication No. SMA 05-4062. Rockville, MD (2005a).
6. JOHNSTON LD, O'MALLEY PM, BACHMAN JG et al.: Monitoring the future national results on adolescent drug use: overview of key findings, 2005. (NIH Publication No. 06-5882). Bethsda, MD: National Institute on Drug Abuse (2006).
7. DOLE V, NYSWANDER. ME, KREEK MJ: Narcotic blockade. Arch. Int. Med. (1966) 118:304-309.
8. FAGGIANO F, VERSINO E, VIGNA-TAGLIANTI F et al.: Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst. Rev. (2000) 2:CDO02208.
9. WALSH SL, PRESTON KL, STITZER ML et al.: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. (1994) 55:569-580.
10. ALTMAN JL, MEYER RE, MIRIN SM, MCNAMEE HB: Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study. Int. J. Addict. (1976) 1(3):485-499.
11. MELLO NK, MENDELSON JH, KUEHNLE JC et al.: Operant analysis of human heroin self-administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. (1981) 216:45-54.
12. TUCKER TK, RITTER A, MAHER C et al.: Natrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev. (2004) 23:299-300.
13. CALLAGHAN E, RAWSON R, MCCLEAVE B: The treatment of heroin addiction using naltrexone alone and with behaviour therapy. Int. J. Addict. (1980) 15:795-807.
14. ANTON RE, HOGAN I, JALALI B et al.: Multiple family therapy and naltrexone in the treatment of opiate-dependence. Drug Alcohol Depend. (1981) 8:157-168.
15. JULIUS D: NIDA's naltrexone research program. In: Narcotic Antagonists: Naltrexone (NIDA Research Monograph No: 9), Julius D, Renault P (Eds), National Institute of Drug Abuse, Rockville, MD, USA (1976):5-11.
16. AZARIAN A, PAPIASVILLI A, JOSEPH H: A study of the use of clonidine and naltrexone in the treatment of opiod addiction in the former USSR. J. Addict. Dis. (1994) 13:35-52.
17. CALLAHAN E, RAWSON R, GLAZER M et al.: Comparison of two naltrexone treatment programs: naltrexone alone versus naltrexone plus behaviour therapy. NIDA Res. Monogr. (1976) 9:150-157.
18. KOSTEN TR, KLEBER HD: Strategies to improve compliance with narcotic antagonists. Am. J. Drug Alcohol Abuse (1984) 10:249-266.
19. SAN L, POMAROL G, PERI JM et al.: Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br. J. Addict. (1991) 86:983-990.
20. HULSE GK, BASSO MR: The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. (2000) 19:41-48.
21. AHMADI J, AHMADI K, OHAERI J: Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J. Clin. Invest. (2003) 33(9):824-829.
22. KIRCHMAYER U, DAVOLI M, VERSTER AD et al.: A systematic review on the efficacy of naltrexone maintenance treatment in opiod dependence. Addiction (2002) 97:1241-1249.
23. ADI Y, JUAREZ-GARCIA A, WANG D et al.: Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol. Assess. (2007) 11: 1-101.
24. HOLLISTER LE, JOHNSON K, BOUKHABZA D et al.: Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. (1981) 8:37-41.
25. CROWLEY TJ, WAGNER JE, ZERBE G et al.: Naltrexone-induced dysphoria in former opioid addicts. Am. J. Psychiatry (1985) 142:1081-1084.
26. ONCKEN C, VAN KIRK J, KRANZLER HR: Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology (2001) 154:397-402.
27. WASHTON AM, POTTASH AC, GOLD MS: Naltrexone in addicted business executives and physicians. J. Clin. Psychiatry (1984) 45:39-41
28. CHAN KY. The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J. Clin. Forensic Med. (1996) 3:87-92.
29. CORNISH JW, METZGER D, WOODY GE et al.: Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat. (1997) 14:529-534.
30. O'BRIEN CP, CORNISH JW: Naltrexone for probationers and parolees. J. Subs. Abuse Treat. (2006) 31:107-111.
31. PRESTON KL, SILVERMAN K, UMBRICHT A et al.: Improvement in naltrexone treatment compliance with contingency management. Drug Akohol Depend. (1999) 54:127-135.
32. CARROLL KM, BALL SA, NICH C et al.: Targeting behavioral therapies to enhance naltrexone treatment of opiod dependence: efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatry (2001) 58:755-761.
33. ROTHENBERG JL, SULLIVAN MA, CHURCH SH et al.: Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. (2002) 23:351-360.
34. FALS-STEWART W, O'FARRELL TJ: Behavioral family counseling and naltrexone for male opiod-dependent patients. J. Consult. Clin. Psychol. (2003) 71:432-442.
35. KRUPITSKY EM, ZVARTAU EE, MASALOV DV et al.: Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J. Subs. Abuse Treat. (2004) 26(4):285-294.
36. YOLLES S, LEAFE TD, WOODLAND JHR et al.: Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites. J. Pharmacol. Sci. (1975) 64:348-349.
37. CHIANG CN, HOLLISTER LE, KISHIMOTO A et al.: Kinetics of a naltrexone sustained-release preparation. Clin. Pharmacol. Ther. (1984) 36:704-708.
38. SHARON AC, WISE DL: Development of drug delivery systems for use in treatment of narcotic addiction. NIDA Res. Monogr. (1980) 28:194-213.
39. MAA YF, HELLER J: Controlled release of naltrexone pamoate from linear poly(orthoesters). J. Control. Release (1990) 14:21-28.
40. BARTUS RT, EMERICH DF, HOTZ J et al.: Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology (2003) 28:1973-1982.
41. MARTIN WR, SANQUIST VL: A sustained release depot for narcotic antagonists. Arch. Gen. Psychiatry (1974) 30:31-33.
42. ABRAHAMS RA, RONEL SH: Biocompatible implants for the sustained zero-order release of narcotic antagonists. Biomed. Mater. Res. (1975) 9:355-366.
43. SCHWOPE AD, WISE DL, HOWES JF: Lactic/glycolic acid polymers as narcotic antagonist delivery systems. Life Sci. (1975) 17:1877-1886.
44. SIDMAN CL, BERCOVICI T, GITLER C: Membrane insertion of lymphocyte surface molecules. Mol. Immunol. (1980) 17:1575-1583.
45. HARRIGAN SE, DOWNS DA: Pharmacological evaluation of narcotic antagonist delivery systems in rhesus monkeys. NIDA Res. Monogr. (1981) 28:77-92.
46. REUNING RH, LIAO SHT, STAUBUS AE et al.: Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery system. J. Pharmacokinet. Biopharm. (1983) 11:369-387.
47. OLSEN JL, KINCL FA: A review of parental sustained-release naltrexone systems, In: Naltrexone Research Monograph. Willette RE, Barnett G (Eds), National Institute on Drug Abuse (1980):187-264.
48. WILLETTE RE: Narcotic antagonists. An alternative for treating opioid dependence. Am. Pharm. (1982) NS22:44-46.
49. BREWER C: Serum naltrexone and 6-β-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict. Biol. (2002) 7:321-323.
50. HAMILTON RJ, OLMEDO RE, SHAH S et al.: Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad. Emerg. Med. (2002) 9:63-68.
51. VEREBY K, VOLAVKA J, MULE SJ et al.: Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin. Pharmacol. Ther. (1976) 20:315-328.
52. NAVARATNAM V. JAMALUDIN A, RAMAN N et al.: Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. (1994) 34:231-236.
53. CHIANG CN, HOLLISTER LE, GILLESPIE HK et al.: Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. (1985) 16:1-8.
54. BREWER C: Naltrexone implants for opiate addiction: new life for a middle aged drug. Pharm. J. (2001) 267:260.
55. HULSE GK, O'NEIL G: A possible role for implantable naltrexone in the management of the 'high risk' pregnant heroin user. Aust. N Z J. Obstet. Gynaecol. (2002) 42:93-94.
56. COMER SD, COLLINS ED, KLEBER HD et al.: Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl.) (2002) 159:351-360.
57. LIN F-H, CHEN T-M, LIN C-P et al.: The merit of sintered PDLLA/TCP composites in management of bone fracture internal fixation. Artif. Organs (1999) 23:186-194.
58. YAMAGUCHI K, ERSON JM: In vivo biocompatibility studies of medisorb 65/35 D,L-lactide/glycolide copolymer microspheres. J. Control. Release (1993) 24:81-93.
59. VERT M, SCHWACH G, ENGEL R et al.: Something new in the field of PLA/GA bioresorbable polymers? J. Control. Release (1998) 53:85-92.
60. JOHNSON BA, AIT-DAOUD N, AUBIN H-J et al.: A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex (R)) in patients with alcohol dependence. Alcohol. Clin. Exp. Res. (2004) 28:1356-1361.
61. THERIN M, CHRISTEL P, LI SM et al.: In vivo degradation of massive poly(a-hydroxyacids): validation of in vitro findings. Biomaterials (1992) 13:594-600.
62. GRIZZI I, GARREAU H, LI S et al.: Hydrolytic degradation of devices based on poly(D,L-lactic acid) size-dependence. Biamaterials (1995) 16:305-311.
63. KRANZLER HR, MODESTO-LOWE V, NUWAYSER ES: Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol. Clin. Exp. Res. (1998) 22:1074-1079.
64. GALLOWAY GP, KOCH M, GROSS J et al.: Safety, tolerability and pharmacokinetics of a sustained-release formulation of naltrexone in alcoholics. Drug Alcohol Depend. (2001) 63:S52.
65. KRANZLER HR, WESSON DR, BILLOT L; DRUG ABUSE SCIENCES NALTREXONE DEPOT STUDY GROUP: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin. Exp. Res. (2004) 28:1051-1059.
66. KAPLAN SA, POULETTY P, WESSON DR. Pharmacokinetics of naltrexonc from polylactide sustained-release naltrexone. Drug Alcohol Depend. (2000) 60:SI07.
67. GARBUTT JC, KRANZLER HR, O'MALLEY SS et al.; VIVITREX STUDY GROUP: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 293:1617-1625.
68. SULLIVAN MA, VOSBURG SK, COMER SD: Depot naltrexone: antagonism of the reinforcing, subjective and physiological effects of heroin. Psychopharmacology (2006) 289:37-46.
69. COMER SD, SULLIVAN MA, YU E et al.: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry (2006) 63:210-218.
70. HULSE GK, ARNOLD-REED DA, O'NEIL G et al.: Achieving long-term continuous blood naltrexone and 6-b-naltrexol coverage following sequential naltrexone implants. Addict. Biol. (2004) 9:67-72.
71. HULSE GK, ARNOLD-REED DA, O'NEIL G et al.: Blood naltrexone and 6-b-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict. Biol. (2004) 9:59-65.
72. HULSE GK, STALENBERG V. MCCALLUM D et al.: Histological changes over time around the site of sustained release naltrexone-poly(D,L-lactide) implants in humans. J. Control Release (2005) 108:43-55.
73. DARKE S, SUNJIC S, ZADOR D et al.: A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Drug Alcohol Depend. (1997) 47:45-53.
74. DARKE S, ROSS J: Heroin-related deaths in South Western Sydney, Australia, 1992 - 1996. Drug Alcohol Rev. (1999) 18:39-45.
75. GEROSTAMOULOS J, STAIKOS V, DRUMMER OH: Heroin-related deaths in Victoria: a review of cases for 1997 and 1998. Drug Alcohol Depend.(2001) 61:123-127.
76. HULSE GK, TAIT RJ, COMER SD et al.: Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. (2005) 79:351-357.
77. KIRCHMAYER U, DAVOLI M, VERSTER A: Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. (2003) 2:CDO01333.
78. SEAMAN SR, BRETTLE RP, GORE SM: Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ (1998) 316:426-428.
79. WHITE JM, IRVINE RJ: Mechanisms of fatal opioid overdose. Addiction (1999) 94:961-972.
80. DARKE S, ROSS J, ZADOR D et al.: Heroin-related deaths in New South Wales, Australia, 1992 - 1996. Drug Alcohol Depend. (2000) 60:141-150.
81. BARDO MT, BHATNAGAR RK, GEBHART GF: Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat. Brain Res. (1983) 289:223-234.
82. BARDO MT, NEISEWANDER JL: Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine. Pharmacol. Biochem. Behav. (1987) 28:267-273.
83. PARONIS CA, HOLTZMAN SG: Increased analgesic potency of μ agonists after continuous naloxone infusion in rats. J. Pharmacol. Exp. Ther. (1991) 259:582-589.
84. PARONIS CA, HOLTZMAN SG: Sensitization and tolerance to the discriminative stimulus effects of μ-opioid agonists. Pychopharmacology (1994) 114:601-610.
85. TEMPEL A, GARNDER EL, ZUKIN RS: Neurochemical and functional correlates of naltrexone-induced opioid receptor up-regulation. J. Pharmacol. Exp. Ther. (1985) 232:439-444.
86. TEMPEL A, GARNDER EL, ZUKIN RS: Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci. (1982) 31:1401-1404.
87. YOBURN BC, INTURRISI CE: Modification of the response to opioid and nonopioid drugs by chronic opioid antagonist treatment. Life Sci. (1988) 42:1689-1696.
88. YOUNG AM, MATTOX SR, DOTY MD: Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone. Pychopharmacology (1991) 103:67-73.
89. UNTERWALD EM, RUBENFELD JM, IMAI Y et al.: Chronic opioid antagonist administration upregulates μ-opioid receptor binding without altering μ-opioid receptor mRNA levels. Mol. Brain Res. (1995) 33:351-355.
90. RITTER AJ: Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust. N Z J. Psychiatry (2002) 36:224-228.
91. DIGUISTO E, SHAKESHAFT A, RITTER A et al.; AND THE NEPOD RESEARCH GROUP 2004: Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction (2004) 99(4):450-460.
92. CORNISH JW, HENSON D, LEVINE S et al.: Naltrexone maintenance: effect on morphine sensitivity in normal volunteers. Am. J. Addict. (1993) 2:34-38.
93. HULSE GK, TAIT RJ: A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in "high risk" adolescent heroin users. Addict. Biol. (2003) 8(3):337-342.
94. GIBSON AE, DEGENHARDT LJ, HALL WD: Opioid overdose deaths can occur in patients with naltrexone implants. Med. J. Aust. (2007) 186:152-153.
95. SAX DDS, KORNETSKY C, KIM A: Lack of hepatotoxicity with naltrexone treatment. J. Clin. Pharmacol. (1994) 34:898-901.
96. MARRAZZI MA, WROBLEWSKI JM, KINZIE J et al.: High-dose naltrexone and liver function safety. Am. J. Addict. (1997) 6:21-29.
97. BRAHEN LS, CAPONE TJ, CAPONE DM: Naltrexone: lack of effect on hepatic enzymes. J. Clin. Pharmacol. (1998) 28:64-70.
98. VOLPICELLI JR, RHINES KC, RHINES JS et al.: Naltrexone and alcohol dependence. Arch. Gen. Psychiatry (1997) 54:737-742.
99. O'BRIEN CP CORNISH JW. Opioid: antagonists and partial agonists. In: Textbook of Substance Abuse Treatment (2nd edn). Galanter M, Kleber HD (Eds) Chapter 25, American Psychiatric Press, Washington DC, USA (1999).
100. KREEK MJ, SCHLUGERJ, BORG L et al.: Dynorphin Al-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J. Pharmacol. Exp. Ther. (1999) 288(l):260-269.